A B S T R A C T The metabolic clearance rate (MCR) of human luteinizing hormone (hLH) has been determined in 10 normal men, 3 normal women, and in 12 women with ovulatory disorders resulting in oligomenorrhea or amenorrhea. The MCR was determined by the constant infusion technique using either iodinated or unlabeled highly purified hLH, and these results were compared to MCR determined by using crude pituitary preparations containing both follicle-stimulating hormone and hLH. Both preparations produced essentially similar results for the MCR of hLH and virtually identical results were obtained when complete or incomplete immunoprecipitation of the infused material was achieved. The MCR/body surface area of hLH was significantly greater in normal men (25.6+3.6 ml/minm2) than in normal premenopausal (19.2±0.9 ml/min. in2) or postmenopausal women (17.4±1.9 ml/min mn). No difference was noted in the MCR of hLH in women with oligomenorrhea or amenorrhea. Production rates (PRs) were calculated by using a pituitary standard, the values being 85.1±21.5 IU/24 h in normal men, 39.9±12.6 IU/24 h in normal premenopausal women, and 294.6±61.9 IU/24 h in normal postmenopausal women. The initial half-times of disappearance of the a-and P-subunits of hLH were measured in two normal men and found to be 15-18 min, respectively. The half-time of intact hLH was twice as great.
INTRODUCTION
This report presents the results of the determination of MCR and PR of hLH in normal men and women and in patients with disturbances of gonadal function. It includes the first preliminary data on the half-time of disappearance of the a-and P-subunits of hLH in normal men. In the calculation of PR, the mean of a number of basal plasma hLH determinations was used to overcome the effect of episodic fluctuations in plasma hLH concentrations. Furthermore, data concerning the fraction of the PR of hLH excreted in urine is presented. The study examines the necessity for quantitative immunological precipitation of the hormone preparation infused in the calculation of MCR and the effects of varying this parameter. It aims to provide base-line data for subsequent investigations of the role of kidney and liver function in the clearance and metabolism of hLH.
METHODS
Subjects. Studies were performed in four groups of subjects, all of whom had given informed consent after careful explanation of the procedure and possible side effects.
(a) 12 21 , and 44 yr, respectively. The first two were studied on day 7 of the cycle, and the third, who had had a hysterectomy previously but still had ovarian function as assessed by cyclical changes in her basal body temperature, was studied in the midfollicular phase.
(d) 12 anovulatory women. Four aged 54-71 yr were postmenopausal; two aged 19 and 20 yr had primary amenorrhea; five aged 25-36 yr had secondary amenorrhea of greater than 12-mo duration; and one, aged 29, had oligomenorrhea with a cycle length of 3-4 mo (see Table I ).
In 20 of the 26 patients studied, a 24-h urine specimen was collected on the day before the study and in the 8 patients with primary amenorrhea, secondary amenorrhea, and oligomenorrhea, the 24-h collections were continued for a further 6 days. All patients were resting in bed and ate normal diets during the study. Those patients given "Ilabeled hLH received 5 drops of Lugol's iodine every 8 h for 24 h before and 48 h after the study in order to block thyroid trapping of radioactive iodine. hLH preparations administered. Three different preparations were employed in the studies, two being highly purified and the other heavily contaminated with follicle-stimulating hormone ( hPG batch 025 was used unlabeled whereas LER 1533 was used unlabeled and after iodination with "I to a specific activity of 100-150 gCi/,ug by the method of Greenwood, Hunter, and Glover (4). Separation of the "2I-labeled hLH from free "2I was achieved by filtration on a 10-cm column of cellulose, the elution buffer being 5% human serum albumin-Veronal at pH 8.6. The fraction selected for infusion showed essentially no damaged [5I]hLH or free "I by chromatoelectrophoretic analysis (5) and 90-95% of added counts were immunoprecipitable with excess antibody under conditions described below. Hennen hLH was labeled and assessed in the same way. All preparations were sterilized by Millipore filtration and cultured before use, the labeled material being stored at 4°C and used as soon as possible after bacteriological assessment.
Subunit preparations administered. The a-and p-subunits from two different preparations of hLH were utilized. Drs. G. Hennen and R. Lequin kindly provided a-hLH (biologic potency 0.05 U NIH hLH SI/mg, OAAD assay) and 8-hLH (0.01 U SI/mg) prepared as previously described (6) . Dr. L. Reichert generously provided a-hLH (LER 1756-2) and P-hLH (LER 1756-1) (7).
Measurement of endogenous hLH. Plasma hLH was determined in a specific double antibody radioimmunoassay described previously from this laboratory (8 were expressed in mIU of the 2nd IRP-HMG. In this assay system, 1 Ag LER 907 is equivalent to 40 mIU hLH.
The sensitivity of the assay was 0.1 mIU/ml and the precision, expressed as the coefficient of variation as calculated by the method of Burger, Lee, and Rennie (9), was less than 6% for values in the range seen in young adult men and women. Interassay variation of duplicate plasma samples in 20 consecutive assays was 10.4%.
This assay system was used to measure hLH levels after infusions or injections of unlabeled hLH for half-time or MCR determinations. Urinary hLH. Urinary hLH was measured by a modification of the method described by Baghdassarian, Guyda, Johanson, Migeon, and Blizzard (10). 5 vol of ethanol rather than acetone were used and two extractions were performed. The standard used was the 2nd IRP-HMG. The sensitivity of the assay was 0.5 mIU/ml urine and the precision, as defined above, was less than 5% for values in the range seen in young adult men and women. Interassay variation of measurements made on duplicate urine extracts in 15 consecutive assays was 11.0%.
Plasma hLH disappearance studies. Disappearance studies were performed in one subj ect with both labeled and unlabeled hLH (LER 1533 B76-93) and with hPG 025. Because of the multiexponential nature of the disappearance curves obtained, the initial plasma half-time of each preparation was defined as the time at which the plasma hormone concentration had fallen to 50% of the peak value achieved after intravenous inj ection, plasma samples being collected every minute for 5 min and then at frequent intervals for 6 h.
MCR determination. The constant infusion technique of Tait (11) was employed in all subjects, one subject also having his MCR determined by measuring the area under the disappearance curve after a single intravenous injection. The plasma volume was determined by the '31I-labeled albumin technique of Wagner (12) .
To allow subsequent calculation of hormone PR, plasma samples were collected every 15 min for 1-3 h before each study for determination of endogenous hormone levels. For the purposes of these experiments, it was assumed that these levels did not change significantly during the infusion. The hormone preparation infused was dissolved in 100 ml of 0.9% saline containing 1% human albumin and 20 ml was given intravenously as a priming dose. 20 min later, the constant infusion was commenced and the remaining 80 ml was usually given over 6-7 h; in two subjects the infusion was continued for a total of 12 h. The effects of varying the loading dose and the time interval between it and the commencement of the constant infusion were evaluated in three subj ects.
Heparinized venous blood samples were drawn every 30 min after the infusion had been in progress for 3 h. In the initial studies, blood samples were drawn after the priming dose and every 30 min for the first 3 h also. It was assumed that equilibrium had been reached if the hormone levels measured in at least five consecutive plasma samples fluctuated around the mean value and differed from it by no more than 6%, this being the coefficient of variation for the routine hLH assay quoted previously. The intra-assay variation of 10 duplicate specimens of the same labeled plateau plasma sample was less than 2%.
For the radioactive studies, the MCR was calculated after the method of Tait and Tait and Burstein (11, 13): antibody-precipitable radioactivity infused per minute divided by antibody-precipitable radioactivity per milliliter of plasma at equilibrium: MCR= (['5I]hLH infused/minute)/(['I]-hLH/milliliter plasma at equilibrium).
For the studies using unlabeled hormone, account was taken of the endogenous levels in calculating the MCR: MCR= (hLH infused/minute)/(Plateau hLH -basal hLH).
Estimation of hLH infused and hLH at plateau. In the studies using unlabeled hormone, the volumes of infusate delivered in two consecutive 5-min samples immediately after the end of the study were determined. To determine the concentration of hLH infused, serial dilutions of the infusate were added to plasma obtained before the infusion, this plasma being subsequently diluted 1: 8 in 1% bovine serum albumin in phosphate-buffered saline. Plasma samples obtained at plateau were similarly diluted 1: 8 and all samples from each patient were analyzed in the same assay. Serial dilutions of both the infusate and the patients' plasma at plateau produced displacement of labeled antigen from hLH antibody parallel to that obtained with the assay standard.
In the studies using radioactive hormone, the percent counts precipitable by antibody remained constant in the infusion system throughout the study and two consecutive 5-min samples were collected at the end of the study to determine the infusion rate. The infused material was diluted in the patient's basal plasma to concentrations of 1/100, 1/200, and 1/400 and then, together with duplicate specimens of the plateau samples, subj ected to double antibody precipitation. Excess rabbit anti-hLH antibody was added to 0.4 ml of duplicate plasma samples, allowed to incubate at 4VC for 24 h, and then goat anti-rabbit gamma-globulin serum added. After a further 16 h, the samples were centrifuged, the supernate removed, and the precipitates counted. The hLH antisera were raised in rabbits against pituitary hLH prepared in our laboratory by the method of StockellHartree (14) and precipitated varying amounts of hLH and FSH (Table II) . All three antisera were employed in some experiments but for the majority of studies of MCR, the Rab 12 antiserum' was used. In two studies, the effect of varying the concentration of the anti-hLH antiserum, used for immunoprecipitation, on the calculation of MCR was evaluated. Furthermore, in another study, duplicate plasma samples were treated with trichloroacetic acid (TCA) in a final concentration of 20%, and the precipitated counts so achieved used to calculate the MCR; this result was compared with the MCR obtained by using immunoprecipitable counts obtained with the three different antisera to hLH.
PRs. PRs were determined from the MCRs from constant infusion and the level of endogenous hormone (i) per milliliter of plasma, this latter value being calculated as the mean of the samples taken every 15 min before the commencement of the study: PR = MCR X i.
Disappearance studies of hLH subunits. Disappearance studies, similar to those described for hLH above, were performed in two subjects by using the Hennen and Reichert subunit preparations. All subunits were labeled with 'I as described above. Three antisera were employed for immunoprecipitation and their characteristics are summarized in Table III (Fig. 1) . However, when the same plasma was assessed by immunoprecipitation, plateau was seen with each antiserum used (Fig. 1) . The continuing rise in radioactivity seen when TCA precipitation was used to assess [ (Table IV) .
The separate study evaluating the effect of different dilutions of the same first and second antibodies also showed no significant difference in the calculated MCR although the percentage of the infused material which was immunoprecipitable varied between 56.3 and 79.7% (Table V) . From these results, complete precipitation of the ['"I]hLH does not appear to be essential for the conduct of such studies.
The specificity of the antibodies used in the studies is shown in Table II , the iodinated hormones used to test this specificity being LER 1533 B76-93 for hLH and LER 1563 for hFSH. This latter preparation, although highly purified, does contain 9.3% contamination with hLH as assessed biologically (FSH 2,900 IU/mg, hLH 270 IU/mg)5 or immunologically (FSH 2,580 IU/mg, hLH 240 IU/mg). Due to limited supplies, Rab. 2 antibody was not used in a concentration greater than 1/60,000. This antiserum is used to measure serum hLH levels routinely at a final dilution of 1/1,800,000 and very little cross-reactivity with FSH was found, the small amount probably being due to labeling of the 9.3% hLH contaminant of the highly purified hFSH. At the concentrations used in the MCR studies however, all the hLH antibodies were nonspecific in that a variable quantity of FSH was precipitated. Because of 'Reichert, L. Personal communication. The basic assumption which needs to be satisfied when the MCR is determined by using labeled material is that the labeled hormone is a true tracer of endogenous secreted hormone. As it was not possible to find a suitable patient having a hypophysectomy performed in whom the disappearance rate of endogenous hLH could be assessed, labeled and unlabeled purified hLH and hPG were injected into the same patient in successive studies and their hLH half-times compared (Table VI) . No significant difference was found and the results obtained were similar to those reported by Schalch, Parlow, Boon, and Reichlin (15) , although the latter authors assumed that the disappearance curve, when Because of the basic similarity in the handling of the hLH preparations shown in Table VI, a comparison was made between the MCR results obtained after constant infusion of labeled and unlabeled hLH in two separate subjects (Table VII) . As shown in Table VII , there is a difference in the MCR result obtained depending on whether or not allowance is made for the endogenous hormone secreted during the infusion. In Table IX . A summary of these results is shown in Table X . The MCR of hLH in normal males of 43.9±8.5 ml/min was significantly greater (P < 0.001) than the values obtained for normal premenopausal or postmenopausal women even if allowance is made for surface area. Despite differences in urinary estrogen and pregnanediol excretion between normal premenopausal women and those in the postmenopausal or anovulatory state, no significant difference was seen in their MCR of hLH.
PR results. The calculated PRs in the various groups of subjects are shown in Table IX . It is noteworthy that the PRs in normal men are approximately the same as those in the women with secondary amenorrhea, whilst in postmenopausal women, the PR is 3-4 times higher. The two women with primary amenorrhea had low PRs while the rate in the man with germinal cell aplasia was greater than those of all the normal men studied. The urinary hLH excretion is also shown in Table IX .
Half-times of disappearance of LH subunits. The initial half-times of disappearance of Hennen hLH in the two subjects studied were 31 and 33 min, respectively. In contrast, as shown in Table VI , the subunit half-times were 15-18 min (a-hLH, both Hennen and Reichert) and 14-17 min (9-hLH, both types). No statistically significant difference was seen, whether the Rab 12 or the anti-a-hLH antisera were used in the a-subunit study, nor was there a difference whether Rab 12 or anti-13-hLH was used for the 3-subunit study. It may therefore be concluded that changes in the peripheral hLH levels in women with intact hepatic and renal function reflect differences in the rates of pituitary secretion rather than differences in disposal rates. Although there is some evidence for uptake and metabolism of hLH by avarian tissue (18) , the possible effects of this factor on overall hormone disposal are insufficient to be reflected in mean MCR estimates.
A striking finding in the present study is the demonstration of a sex difference in the handling of a pituitary gonadotropin. The MCR of hLH in the 11 men studied (43.5+8.2, mean+SD ml/min) was significantly greater than in the 15 women (29.7±3.7 ml/min), and the difference remained statistically significant when allowance was made for differences in body surface area. On this basis, the MCR of hLH was 29% higher in men than in women.
The reason for and biologic significance of this sex difference are obscure. Although there is little evidence in favor of the presence of specific serum binding proteins for the protein and polypeptide hormones, Rajaniemi and Vanha-Perttula (19) have reported the binding of hLH and FSH to rat and human serum proteins. Even so, they stated that there were no apparent differences in this binding in sera from normal men, normal menstruating women, pregnant, and postmenopausal women. Thus, it is unlikely that protein binding of hLH is responsible for the sex difference in the MCR.
The method of estimating MCR was validated in several ways, but it must be emphasized that the clearance (20) indicates that the a-subunit is the one predominantly labeled with 'I, at least as regards the porcine hormone. The data reported here for the first time, that the initial plasma half-times of a-and #-hLH are approximately half that of the intact molecule, provides a strong argument against the above criticism.
A major problem in the reporting of the present data, and its comparison with other reports, concerns the choice of the appropriate standard to be used to express the units of hLH PR. Kohler et al. (2) expressed the plasma concentration of hLH in terms of 2nd IRP-HMG, and used the figures derived for PR to conclude that the pituitary content of hLH turned over once per day. It is now well recognized (21) that a pituitary standard should be used for the estimation of the potency of pituitary gonadotropin preparations, since the use of a urinary standard such as 2nd IRP-HMG will give a relative estimate of potency 5-6 times higher than that of the bioassay using 2nd IRP-HMG as standard. The appropriate standard to be used for estimates of plasma concentration remains a matter of controversy (22) , but there has been a general tendency in recent years to employ a pituitary standard (e.g., Medical Research Council Standards, LER 907). In the present study, a pituitary standard has been employed, the units being those of its biological potency in terms of 2nd IRP-HMG. As a result, the range of values obtained for PR of hLH differs significantly from the report of Kohler et al. (2) . These authors calculated a PR of 734±+170 mU/min (equivalent to 1,060±245 IU/day) in normal women, and 2,400 mU/min (3, 450 IU/day) in post-menopausal women. The corresponding figures in the present study were 39.9 IU/day in two normal women and 295 IU/day in postmenopausal women. These striking differences can be attributed almost entirely to differences in the estimated plasma concentrations of endogenous hLH, the differences being due to the use of different immunoassays.
The interpretation of values obtained for urinary excretion of hLH also presents difficulty. From the data presented here, it can be concluded that of the measured PR of hLH in normal men (85.1±21.5 IU/day), approximately 41% is excreted in the urine, when the uri- 
